Head to Head Analysis: Jupiter Neurosciences (NASDAQ:JUNS) vs. Eloxx Pharmaceuticals (NASDAQ:ELOX)

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.

Valuation & Earnings

This table compares Eloxx Pharmaceuticals and Jupiter Neurosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	11.15	-$5.99 million	($1.54)	-11.40
Jupiter Neurosciences	$20,000.00	136.95	-$8.65 million	($19.12)	-0.16

Eloxx Pharmaceuticals has higher revenue and earnings than Jupiter Neurosciences. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eloxx Pharmaceuticals and Jupiter Neurosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Jupiter Neurosciences	N/A	-1,314.62%	-246.66%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Eloxx Pharmaceuticals and Jupiter Neurosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	1	2.75
Jupiter Neurosciences	1	0	0	0	1.00

Eloxx Pharmaceuticals currently has a consensus target price of $41.50, suggesting a potential upside of 136.47%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Eloxx Pharmaceuticals is more favorable than Jupiter Neurosciences.

Insider & Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 38.6% of Jupiter Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its stock price is 186,326% less volatile than the S&P 500. Comparatively, Jupiter Neurosciences has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Summary

Eloxx Pharmaceuticals beats Jupiter Neurosciences on 10 of the 14 factors compared between the two stocks.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.